- Home
- OTLK vs ATON Comparison
OTLK vs ATON Comparison
Compare OTLK & ATON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- ATON
- Stock Information
- Founded
- OTLK 2010
- ATON 1973
- Country
- OTLK United States
- ATON British Virgin Islands
- Employees
- OTLK N/A
- ATON N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- ATON Oil & Gas Production
- Sector
- OTLK Health Care
- ATON Energy
- Exchange
- OTLK Nasdaq
- ATON Nasdaq
- Market Cap
- OTLK 42.8M
- ATON 37.1M
- IPO Year
- OTLK 2016
- ATON N/A
- Fundamental
- Price
- OTLK $1.21
- ATON $4.74
- Analyst Decision
- OTLK Buy
- ATON
- Analyst Count
- OTLK 5
- ATON 0
- Target Price
- OTLK $5.25
- ATON N/A
- AVG Volume (30 Days)
- OTLK 1.4M
- ATON 1.8M
- Earning Date
- OTLK 08-14-2025
- ATON 11-25-2025
- Dividend Yield
- OTLK N/A
- ATON N/A
- EPS Growth
- OTLK N/A
- ATON N/A
- EPS
- OTLK N/A
- ATON N/A
- Revenue
- OTLK $1,505,322.00
- ATON N/A
- Revenue This Year
- OTLK N/A
- ATON N/A
- Revenue Next Year
- OTLK $342.80
- ATON N/A
- P/E Ratio
- OTLK N/A
- ATON N/A
- Revenue Growth
- OTLK N/A
- ATON N/A
- 52 Week Low
- OTLK $0.79
- ATON $2.95
- 52 Week High
- OTLK $6.98
- ATON $15.82
- Technical
- Relative Strength Index (RSI)
- OTLK 45.22
- ATON N/A
- Support Level
- OTLK $1.28
- ATON N/A
- Resistance Level
- OTLK $1.31
- ATON N/A
- Average True Range (ATR)
- OTLK 0.09
- ATON 0.00
- MACD
- OTLK -0.01
- ATON 0.00
- Stochastic Oscillator
- OTLK 0.00
- ATON 0.00
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ATON AlphaTON Capital Corp. Common Stock
AlphaTON Capital Corp is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, it provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform.